165 related articles for article (PubMed ID: 12564661)
1. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
Curr Med Res Opin; 2002; 18(8):499-502. PubMed ID: 12564661
[TBL] [Abstract][Full Text] [Related]
2. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
[TBL] [Abstract][Full Text] [Related]
3. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
5. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus.
Athyros VG; Papageorgiou AA; Symeonidis AN; Didangelos TP; Pehlivanidis AN; Bouloukos VI; Mikhailidis DP;
Angiology; 2003; 54(6):679-90. PubMed ID: 14666956
[TBL] [Abstract][Full Text] [Related]
6. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Mercouris BR; Pehlivanidis A; Bouloukos VI; Elisaf M;
Curr Med Res Opin; 2004 May; 20(5):627-37. PubMed ID: 15171226
[TBL] [Abstract][Full Text] [Related]
7. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD;
Lancet; 2006 Sep; 368(9539):919-28. PubMed ID: 16962881
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
11. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
Athyros VG; Kakafika AI; Papageorgiou AA; Paraskevas KI; Tziomalos K; Anagnostis P; Pagourelias E; Koumaras C; Karagiannis A; Mikhailidis DP
Curr Med Res Opin; 2008 Jun; 24(6):1593-9. PubMed ID: 18430270
[TBL] [Abstract][Full Text] [Related]
12. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
[TBL] [Abstract][Full Text] [Related]
13. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
März W; Wollschläger H; Klein G; Neiss A; Wehling M
Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
Leibovitz E; Harats D; Gavish D
Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
[TBL] [Abstract][Full Text] [Related]
16. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
[TBL] [Abstract][Full Text] [Related]
17. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Mikhailidis DP; Wierzbicki AS
Curr Med Res Opin; 2002; 18(4):215-9. PubMed ID: 12201622
[No Abstract] [Full Text] [Related]
18. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
